The estimated Net Worth of David Dantzker is at least $2.18 Million dollars as of 19 January 2024. David Dantzker owns over 3,932 units of Surmodics stock worth over $1,572,888 and over the last 19 years he sold SRDX stock worth over $451,994. In addition, he makes $151,000 as Independent Director at Surmodics.
David has made over 9 trades of the Surmodics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 3,932 units of SRDX stock worth $94,171 on 19 January 2024.
The largest trade he's ever made was exercising 23,024 units of Surmodics stock on 3 March 2015 worth over $276,979. On average, David trades about 978 units every 78 days since 2006. As of 19 January 2024 he still owns at least 40,094 units of Surmodics stock.
You can see the complete history of David Dantzker stock trades at the bottom of the page.
Dr. David R. Dantzker M.D. serves as Independent Director of the Company. He has been a director of the Company since January 2011. Dr. Dantzker has been a Partner at Wheatley MedTech Partners L.P., a venture capital fund, since 2001. He manages Wheatley’s Life Science and Healthcare investments. From 1997 to 2000, Dr. Dantzker was President of North Shore-LIJ Health System, a large academic health care system. He also co-founded the North Shore-LIJ Research Institute to direct and coordinate basic science research for the North Shore-LIJ Health System. He is a former Chair of the American Board of Internal Medicine, the largest physician-certifying board in the United States. Dr. Dantzker served on the board of directors of Datascope Corp. from January 2008 until its sale in January 2009. Dr. Dantzker holds a B.A. in Biology from New York University, and received his M.D. from the State University of New York at Buffalo School of Medicine. He sits on the board of directors of Oligomerix, Inc., a Wheatley MedTech portfolio company. Dr. Dantzker is Vice Chair and Chief Medical Officer of Origin, Inc., and a senior advisor to Valience Health in Mumbai, India. He served on the board of Comprehensive Clinical Development, an entity that filed for Chapter 11 bankruptcy protection in March 2013. Dr. Dantzker has also served on the faculty and in leadership positions of four major research-oriented medical schools, has authored or co-authored 130 research papers and five textbooks and is an internationally recognized expert in the area of pulmonary medicine and critical care.
As the Independent Director of Surmodics, the total compensation of David Dantzker at Surmodics is $151,000. There are 14 executives at Surmodics getting paid more, with Gary Maharaj having the highest compensation of $2,343,630.
David Dantzker is 76, he's been the Independent Director of Surmodics since 2011. There are no older and 20 younger executives at Surmodics.
David's mailing address filed with the SEC is C/O WHEATLEY PARTNERS, L.P., 80 CUTTERMILL ROAD, GREAT NECK, NY, 11021.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj, and Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: